Literature DB >> 34910609

The Efficiency of Moses Technology Holmium Laser for Treating Renal Stones During Flexible Ureteroscopy: Relationship Between Stone Volume, Time, and Energy.

Sami E Majdalany1, Brandon A Levin2, Khurshid R Ghani1.   

Abstract

Introduction: There are limited data on how stone factors relate to flexible ureteroscopy (f-URS) laser lithotripsy efficiency and outcomes when using the Moses Technology Ho:YAG system. We examined the relationship of stone volume and density to lithotripsy, lasing times, and energy used to treat a single renal stone. We also assessed short-term clinical outcomes.
Methods: We analyzed patients undergoing f-URS by a single surgeon using high-power Moses Technology Ho:YAG system (Lumenis). We only included cases with a CT confirming a solitary renal stone. Ureteral stones, staged and bilateral procedures were excluded. Stone dimensions and HU were obtained. Volume (mm3) was calculated using European Association of Urology criteria. Laser energy (J), lithotripsy, and lasing times were obtained. Laser activity was calculated by dividing lasing time by lithotripsy time. Relationships between time, stone density, volume, and energy were assessed using Spearman correlation. Complications were assessed using Clavien-Dindo grade. Residual fragments (RF) were determined on imaging within 3 months.
Results: Twenty-nine patients met the inclusion criteria. Mean (range) stone volume and density were 290 mm3 (42-1700) and 814 HU (170-1675), respectively. Mean lithotripsy and lasing times were 11.9 (3.6-26.0) and 6.0 (0.6-19.6) minutes, respectively. Mean laser activity was 47%. Mean fragmentation speed was 0.9 mm3/s. Mean energy used per unit stone volume was 38.2 J/mm3. Time taken to perform fragmentation had a stronger association with the stone volume vs stone density. Three (10.3%) and 2 (6.9%) patients had a Clavien Grade 1 and 2 complications, respectively. At follow-up the zero-fragment rate was 79.3%. Conclusions: When using the Moses Technology laser to ablate a single renal stone with f-URS, the fragmentation speed was ∼1 mm3/s. Stone volume, not density was correlated to lasing time. We propose mm3/s be considered a measure that has implications for technique efficiency and comparing laser platforms.

Entities:  

Keywords:  Moses Technology; holmium:YAG; laser; lithotripsy

Mesh:

Year:  2021        PMID: 34910609     DOI: 10.1089/end.2021.0592

Source DB:  PubMed          Journal:  J Endourol        ISSN: 0892-7790            Impact factor:   2.942


  5 in total

1.  Initial clinical experience with the thulium fiber laser from Quanta System: First 50 reported cases.

Authors:  Alba Sierra; Mariela Corrales; Merkourios Kolvatzis; Olivier Traxer
Journal:  World J Urol       Date:  2022-07-21       Impact factor: 3.661

Review 2.  Understanding cavitation-related mechanism of therapeutic ultrasound in the field of urology: Part I of therapeutic ultrasound in urology.

Authors:  Sung Yong Cho; Ohbin Kwon; Seong-Chan Kim; Hyunjae Song; Kanghae Kim; Min Joo Choi
Journal:  Investig Clin Urol       Date:  2022-05-26

Review 3.  New Generation Pulse Modulation in Holmium:YAG Lasers: A Systematic Review of the Literature and Meta-Analysis.

Authors:  Antoni Sánchez-Puy; Alejandra Bravo-Balado; Pietro Diana; Michael Baboudjian; Alberto Piana; Irene Girón; Andrés K Kanashiro; Oriol Angerri; Pablo Contreras; Brian H Eisner; Josep Balañà; Francisco M Sánchez-Martín; Félix Millán; Joan Palou; Esteban Emiliani
Journal:  J Clin Med       Date:  2022-06-04       Impact factor: 4.964

4.  The clinical efficiency and safety of 60W superpulse thulium fiber laser in retrograde intrarenal surgery.

Authors:  Chandra Mohan Vaddi; Paidakula Ramakrishna; Soundarya Ganeshan; Siddalinga Swamy; Hemnath Anandan; Manas Babu; Rakesh Panda
Journal:  Indian J Urol       Date:  2022-07-01

Review 5.  Moses and Moses 2.0 for Laser Lithotripsy: Expectations vs. Reality.

Authors:  Mariela Corrales; Alba Sierra; Olivier Traxer
Journal:  J Clin Med       Date:  2022-08-18       Impact factor: 4.964

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.